A Randomised, Double-blind, Placebo-controlled, Phase I Study of Orally Administered AK0529 in Chinese Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2018
At a glance
- Drugs AK 0529 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ark Biosciences
- 29 Jun 2018 Status changed from recruiting to completed.
- 03 Nov 2017 Status changed from active, no longer recruiting to recruiting.
- 30 Oct 2017 New trial record